Antipyretic Therapy in Critically Ill Septic Patients: A Systematic Review and Meta-Analysis

Anne M Drewry, Enyo A Ablordeppey, Ellen T Murray, Carolyn R T Stoll, Sonya R Izadi, Catherine M Dalton, Angela C Hardi, Susan A Fowler, Brian M Fuller, Graham A Colditz, Anne M Drewry, Enyo A Ablordeppey, Ellen T Murray, Carolyn R T Stoll, Sonya R Izadi, Catherine M Dalton, Angela C Hardi, Susan A Fowler, Brian M Fuller, Graham A Colditz

Abstract

Objective: This meta-analysis aimed to examine the impact of antipyretic therapy on mortality in critically ill septic adults.

Data sources: Literature searches were implemented in Ovid Medline, Embase, Scopus, Cumulative Index of Nursing and Allied Health Literature, Cochrane Central Register of Controlled Trials, NHS Economic Evaluation Database, and ClinicalTrials.gov through February 2016.

Study selection: Inclusion criteria were observational or randomized studies of septic patients, evaluation of antipyretic treatment, mortality reported, and English-language version available. Studies were excluded if they enrolled pediatric patients, patients with neurologic injury, or healthy volunteers. Criteria were applied by two independent reviewers.

Data extraction: Two reviewers independently extracted data and evaluated methodologic quality. Outcomes included mortality, frequency of shock reversal, acquisition of nosocomial infections, and changes in body temperature, heart rate, and minute ventilation. Randomized and observational studies were analyzed separately.

Data synthesis: Eight randomized studies (1,507 patients) and eight observational studies (17,432 patients) were analyzed. Antipyretic therapy did not reduce 28-day/hospital mortality in the randomized studies (relative risk, 0.93; 95% CI, 0.77-1.13; I = 0.0%) or observational studies (odds ratio, 0.90; 95% CI, 0.54-1.51; I = 76.1%). Shock reversal (relative risk, 1.13; 95% CI, 0.68-1.90; I = 51.6%) and acquisition of nosocomial infections (relative risk, 1.13; 95% CI, 0.61-2.09; I = 61.0%) were also unchanged. Antipyretic therapy decreased body temperature (mean difference, -0.38°C; 95% CI, -0.63 to -0.13; I = 84.0%), but not heart rate or minute ventilation.

Conclusions: Antipyretic treatment does not significantly improve 28-day/hospital mortality in adult patients with sepsis.

Figures

Figure 1.
Figure 1.
Flowchart of study selection.
Figure 2.
Figure 2.
Results of meta-analysis for 28 days per hospital mortality in (A) randomized studies and (B) observational studies. A relative risk (RR) or odds ratio (OR) less than 1 favors antipyretic therapy. The size of the grey box corresponds to weight in the random effects analysis. NSAID = nonsteroidal anti-inflammatory drug.
Figure 3.
Figure 3.
Extended funnel plot demonstrating the effect size and se combinations required of an additional randomized study to change the results of this meta-analysis using a fixed effects model with an alpha level of 0.05. Black dots represent the effect size and ses of the included randomized studies. To change the results of the meta-analysis to favor antipyretics, an additional study would need to have an effect estimate and se combination that falls in the dark grey shaded area. Note that none of the current studies have an effect size-se in the dark grey region; this suggests that the results of the meta-analysis would be robust to an additional study.

References

    1. Lagu T, Rothberg MB, Shieh MS, et al. Hospitalizations, costs, and outcomes of severe sepsis in the United States 2003 to 2007. Crit Care Med 2012; 40:754–761
    1. Kushimoto S, Gando S, Saitoh D, et al. JAAM Sepsis Registry Study Group: The impact of body temperature abnormalities on the disease severity and outcome in patients with severe sepsis: An analysis from a multicenter, prospective survey of severe sepsis. Crit Care 2013; 17:R271.
    1. Young PJ, Saxena M, Beasley R, et al. Early peak temperature and mortality in critically ill patients with or without infection. Intensive Care Med 2012; 38:437–444.
    1. Evans SS, Repasky EA, Fisher DT.Fever and the thermal regulation of immunity: The immune system feels the heat. Nat Rev Immunol 2015; 15:335–349
    1. Lee CT, Zhong L, Mace TA, et al. Elevation in body temperature to fever range enhances and prolongs subsequent responsiveness of macrophages to endotoxin challenge. PLoS One 2012; 7:e30077.
    1. Small PM, Täuber MG, Hackbarth CJ, et al. Influence of body temperature on bacterial growth rates in experimental pneumococcal meningitis in rabbits. Infect Immun 1986; 52:484–487
    1. Chu CM, Tian SF, Ren GF, et al. Occurrence of temperature-sensitive influenza A viruses in nature. J Virol 1982; 41:353–359
    1. Mackowiak PA, Marling-Cason M, Cohen RL.Effects of temperature on antimicrobial susceptibility of bacteria. J Infect Dis 1982; 145:550–553
    1. Jiang Q, Cross AS, Singh IS, et al. Febrile core temperature is essential for optimal host defense in bacterial peritonitis. Infect Immun 2000; 68:1265–1270
    1. Kluger MJ, Ringler DH, Anver MR.Fever and survival. Science 1975; 188:166–168
    1. Frankenfield DC, Smith JS, Jr, Cooney RN, et al. Relative association of fever and injury with hypermetabolism in critically ill patients. Injury 1997; 28:617–621
    1. Manthous CA, Hall JB, Olson D, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med 1995; 151:10–14
    1. Haupt MT, Rackow EC.Adverse effects of febrile state on cardiac performance. Am Heart J 1983; 105:763–768
    1. Niven DJ, Laupland KB, Tabah A, et al. EUROBACT Investigators: Diagnosis and management of temperature abnormality in ICUs: A EUROBACT investigators’ survey. Crit Care 2013; 17:R289.
    1. Zhang Z, Chen L, Ni H.Antipyretic therapy in critically ill patients with sepsis: An interaction with body temperature. PLoS One 2015; 10:e0121919.
    1. Lee BH, Inui D, Suh GY, et al. Fever and Antipyretic in Critically ill patients Evaluation (FACE) Study Group: Association of body temperature and antipyretic treatments with mortality of critically ill patients with and without sepsis: Multi-centered prospective observational study. Crit Care 2012; 16:R33.
    1. Yang YL, Liu DW, Wang XT, et al. Body temperature control in patients with refractory septic shock: Too much may be harmful. Chin Med J (Engl) 2013; 126:1809–1813
    1. Jefferies S, Weatherall M, Young P, et al. The effect of antipyretic medications on mortality in critically ill patients with infection: A systematic review and meta-analysis. Crit Care Resusc 2011; 13:125–131
    1. Niven DJ, Stelfox HT, Laupland KB.Antipyretic therapy in febrile critically ill adults: A systematic review and meta-analysis. J Crit Care 2013; 28:303–310
    1. Serpa Neto A, Pereira VG, Colombo G, et al. Should we treat fever in critically ill patients? A summary of the current evidence from three randomized controlled trials. Einstein (Sao Paulo) 2014; 12:518–523
    1. Zhang Z.Antipyretic therapy in critically ill patients with established sepsis: A trial sequential analysis. PLoS One 2015; 10:e0117279.
    1. Moher D, Liberati A, Tetzlaff J, et al. PRISMA Group: Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. BMJ 2009; 339:b2535.
    1. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008–2012
    1. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)–a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform 2009; 42:377–381
    1. Rohatgi AWebPlotDigitizer Version 3.9. October 2015. Available at: . Accessed February 10, 2016
    1. Schortgen F, Clabault K, Katsahian S, et al. Fever control using external cooling in septic shock: A randomized controlled trial. Am J Respir Crit Care Med 2012; 185:1088–1095
    1. Young P, Saxena M, Bellomo R, et al. HEAT Investigators; Australian and New Zealand Intensive Care Society Clinical Trials Group: Acetaminophen for fever in critically ill patients with suspected infection. N Engl J Med 2015; 373:2215–2224
    1. Deeks JJ, Higgins JPT, Altman DG, et al. Higgins JPT, Green S.Analysing data and undertaking meta-analyses. Cochrane Handbook for Systematic Reviews of Interventions 2011. Available at: The Cochrane Collaboration, . Accessed Februrary 10, 2016
    1. Higgins JPT, Altman DG, Sterne JAC, et al. Higgins JPT, Green S.Assessing risk of bias in included studies. Cochrane Handbook for Systematic Reviews of Interventions 2011. The Cochrane Collaboration, Available at: . Accessed February 10, 2016
    1. Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses. 2014. Available at: . Accessed February 10, 2016.
    1. Reeves BC, Deeks JJ, Higgins JPT, et al. Higgins JPT, Green S.Including non-randomised studies. Cochrane Handbook for Systematic Reviews of Interventions 2011. The Cochrane Collaboration, Available at: . Accessed February 10, 2016
    1. DerSimonian R, Laird N.Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177–188
    1. Wan X, Wang W, Liu J, et al. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol 2014; 14:135.
    1. Crowther MJ, Langan D, Sutton AJ.Graphical augmentations to the funnel plot to assess the impact of a new study on an existing meta-analysis. The Stata Journal 2012; 12:606–622
    1. Langan D, Higgins JP, Gregory W, et al. Graphical augmentations to the funnel plot assess the impact of additional evidence on a meta-analysis. J Clin Epidemiol 2012; 65:511–519
    1. Crowther MJ, Hinchliffe SR, Donald A, et al. Simulation-based sample-size calculation for designing new clinical trials and diagnositic test accuracy studies to update an existing meta-analysis. Stata J 2013; 13:451–473
    1. Sutton AJ, Cooper NJ, Jones DR, et al. Evidence-based sample size calculations based upon updated meta-analysis. Stat Med 2007; 26:2479–2500
    1. Bernard GR, Reines HD, Halushka PV, et al. Prostacyclin and thromboxane A2 formation is increased in human sepsis syndrome. Effects of cyclooxygenase inhibition. Am Rev Respir Dis 1991; 144:1095–1101
    1. Haupt MT, Jastremski MS, Clemmer TP, et al. Effect of ibuprofen in patients with severe sepsis: A randomized, double-blind, multicenter study. The ibuprofen study group. Crit Care Med 1991; 19:1339–1347
    1. Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. The ibuprofen in sepsis study group. N Engl J Med 1997; 336:912–918
    1. Memiş D, Karamanlioğlu B, Turan A, et al. Effects of lornoxicam on the physiology of severe sepsis. Crit Care 2004; 8:R474–R482
    1. Niven DJ, Stelfox HT, Léger C, et al. Assessment of the safety and feasibility of administering antipyretic therapy in critically ill adults: A pilot randomized clinical trial. J Crit Care 2013; 28:296–302
    1. Janz DR, Bastarache JA, Rice TW, et al. Acetaminophen for the Reduction of Oxidative Injury in Severe Sepsis Study Group: Randomized, placebo-controlled trial of acetaminophen for the reduction of oxidative injury in severe sepsis: The acetaminophen for the reduction of oxidative injury in severe sepsis trial. Crit Care Med 2015; 43:534–541
    1. Pestaña D, Casanova E, Villagrán MJ, et al. Continuous hemofiltration in hyperthermic septic shock patients. J Trauma 2007; 63:751–756
    1. Selladurai S, Eastwood GM, Bailey M, et al. Paracetamol therapy for septic critically ill patients: A retrospective observational study. Crit Care Resusc 2011; 13:181–186
    1. Mohr NM, Fuller BM, McCammon CA, et al. Antipyretic use does not increase mortality in emergency department patients with severe sepsis. Acad Emerg Med 2012; 19:S161–S162
    1. Mohr N, Skrupky L, Fuller B, et al. Early antipyretic exposure does not increase mortality in patients with gram-negative severe sepsis: A retrospective cohort study. Intern Emerg Med 2012; 7:463–470
    1. Janz DR, Bastarache JA, Peterson JF, et al. Association between cell-free hemoglobin, acetaminophen, and mortality in patients with sepsis: An observational study. Crit Care Med 2013; 41:784–790
    1. Suzuki S, Eastwood GM, Bailey M, et al. Paracetamol therapy and outcome of critically ill patients: A multicenter retrospective observational study. Crit Care 2015; 19:162.
    1. Mohr NM, Doerschug KC.Point: Should antipyretic therapy be given routinely to febrile patients in septic shock? Yes. Chest 2013; 144:1096–1098; discussion 1101

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅